ClinicalTrials.gg
RecruitingNCT06956703NAZAUpdated Jul 8, 2026

NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study

An observational study in Gastro-Intestinal Disorder, Crohn Disease and Ulcerative Colitis, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-08.

Primary conditionInflammatory Bowel DiseasesRegistry: Digestive System DiseasesReclassifiedWhy we changed it
Registry
Digestive System Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Inflammatory Bowel Diseases
Why
  1. The study's listed conditions name Inflammatory Bowel Diseases, a narrower term within Digestive System Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Nottingham · Observational

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom — 20 open to participants now, 28 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United Kingdom.

Planned enrollment
19th of 42
240 · median 215
Started
2022
with 5 others
Observational
42 of 112
9 open now
Primary completion
2026-12
later than 12 of 27 live
Registered
108th of 112
by date

Among the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 42 observational ones that give a count, is one of 6 that started in 2022, is one of 42 observational ones, reaches primary completion later than 12 of the 27 other live ones, and was the 108th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

20 of the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 16 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the comparisons of inflammatory markers between IBD and non-IBD (control) participants.

The main question it aims to answer is:

Are there differences in inflammatory markers between IBD and non-IBD (control) participants.

Read the detailed description

A cohort study in patients with moderate to severely active Crohns Disease (CD) and Ulcerative Colitis (UC) who are switching to new targeted biologic therapy (with a different mode of action) - onto either anti-TNFα therapy or vedolizumab for UC or onto anti-TNFα therapy or ustekinumab or upadacitinib for CD and undergoing routine endoscopic assessments as part of normal clinical practice.

The investigator will also recruit participants without these conditions (controls) who are due for a lower GI colonoscopy as part of the UK national bowel cancer screening programme or on any hospital/ medical/ clinical screening list or any other appropriate list with no pathology found on examination.

CD \& UC patients will provide blood and stool samples at 3 timepoints (baseline, 3mths, 12mths) as well as extra tissue biopsies taken at standard care endoscopies within 12mths. Controls will provide a blood sample and stool sample as well as extra tissue biopsies taken at standard care colonoscopies.

Samples will be analysed to characterise any observable traits (phenotype) and molecular variability in patients which may be associated with clinical response to the treatment.

The investigator hopes the information gained from this study may help improve the understanding of Inflammatory Bowel Diseases (IBD) and help to develop better ways of treating the condition and predicting the course of the disease and how patients may respond to different treatments.

03

Conditions studied

  • Gastro-Intestinal Disorder
  • Crohn Disease
  • Ulcerative Colitis
  • Inflammatory Bowel Diseases
04

In context

Inflammatory Bowel Diseases Reclassified

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

This study's planned enrollment of 240 is above the median of 140 across 626 observational studies indexed under Inflammatory Bowel Diseases.

Browse Inflammatory Bowel Diseases studies →

Lead sponsor

University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.

Compared within Inflammatory Bowel Diseases, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Digestive System Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

A cohort study in patients with moderate to severely active Crohn's Disease (CD) and Ulcerative Colitis (UC) who are switching to new targeted biologic therapy (with a different mode of action) - onto either anti-TNFα therapy or vedolizumab for UC or onto anti-TNFα therapy or ustekinumab or upadacitinib for CD and undergoing routine endoscopic assessments as part of normal clinical practice.

We will also recruit participants without these conditions (controls) who are due for a lower GI colonoscopy as part of the UK national bowel cancer screening programme or on any hospital/ medical/ clinical screening list or any other appropriate list with no pathology found on examination.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Provision of signed and dated, written before any study specific procedures

AND

2a. Patients of at least 16 years of age with active Crohn's disease defined as: CRP > = 5 mg/L OR FCP > = 250 μg/g OR Visible ulcerations on ileocolonoscopy with a total SES-CD > = 7, or > = 4 if disease is confined to the terminal ileum OR visable active disease on cross-sectional imaging. Are switching to a new mechanism of action (MOA) onto anti-TNF therapy or ustekinumab or upadacitinib

OR

2b. Patients of at least 16 years (no upper age limit) with active UC defined as: CRP > = 5 mg/L OR FCP > = 250 μg/g OR Mayo endoscopy subscore > = 2. Are switching to a new mechanism of action (MOA) onto either anti-TNFα therapy or vedolizumab

OR

2c. Non-IBD participants who are attending for a lower GI colonoscopy at any participating site. On any hospital/ medical/ clinical screening list or any other appropriate list with no pathology found on examination.

Exclusion criteria

Exclusion Criteria:

  1. Inability to give
  2. Any positive result from previous screening for serum surface antigen, or (HIV)
  3. An ongoing infection requiring treatment
  4. Clinical evidence of active COVID infection and/or evidence of active COVID determined by local standard care procedures
  5. Participation in a clinical study with pharmacological intervention within 3 months prior to Baseline visit.
  6. Current diagnosis of cancer
  7. Having received a solid organ or stem cell transplant
  8. Having received a transfusion of blood, plasma, or within 120 days prior to enrolment
  9. Confirmed pregnancy at time of enrolment
  10. For non-IBD participants: A prior history of IBD (CD, UC, microscopic colitis, indeterminate colitis or IBD unspecified)
  11. Clinical judgement by the investigator that the patient should not participate in the study
  12. Under 16yrs of age
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No

Groups and cohorts

  • Crohn's Disease - anti-TNFα therapy

    Consultant will prescribe biologic dose, frequency and duration as normal standard of care

  • Crohn's Disease - ustekinumab

    Consultant will prescribe biologic dose, frequency and duration as normal standard of care

  • Crohn's Disease - upadacitinib

    Consultant will prescribe biologic dose, frequency and duration as normal standard of care

  • Ulcerative Colitis - anti-TNFα therapy

    Consultant will prescribe biologic dose, frequency and duration as normal standard of care

  • Ulcerative Colitis - vedolizumab

    Consultant will prescribe biologic dose, frequency and duration as normal standard of care

  • Control non-IBD

    No biologic will be prescribed

07

What researchers measure

Primary outcomes

  1. The comparison of the IL-23/Th17 inflammatory axis between IBD and healthy control samples

    Time frame: Baseline, Month 3 and Month 12

Secondary outcomes

  1. Characterisation of IL-23/Th17 inflammatory axis within IBD biosamples stratified by prior biologic exposure

    Time frame: Baseline, Month 3 and Month 12

  2. Comparison of mRNA sequencing readouts, characterisation of tissue and immune cell populations, characterisation of protein expression and characterisation of microbial species in the stool and tissue

    The above will be stratified by disease type and status, demographic features of the participant, biologic exposure, clinical and endoscopic response to treatment

    Time frame: Baseline, Month 3 and Month 12

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.

Of 244 non-industry observational studies under Inflammatory Bowel Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 132. This study's planned 48 months is above that.

Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 4, 2025
StartActual
Dec 12, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06956703
Responsible party
Sponsor
First posted
May 4, 2025
Start date
Dec 12, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 8, 2026

Study contacts

Gordon Moran Professor
Contact
Gordon.Moran@nottingham.ac.uk
0115 9249924 ext. 80608
Nadia Frowd
Contact
nadia.frowd1@nhs.net
Gordon Moran Professor
principal investigator · University of Nottingham

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion